The effect of live, attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of patients with multiple sclerosis or clinically isolated syndrome

Journal of Neuroimmunology

Volumn 235, Issue 1-2, 2011, Pages 98-103

  Ahlgren, Cecilia ^a   Odén, Anders ^b   Haghighi, Sara ^a   Andersen, Oluf ^a   Bergström, Tomas ^a   Lycke, Jan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Attenuated vaccine; Cerebrospinal fluid; Diagnosis; Measles; Multiple sclerosis; Viral antibodies

Indexed keywords

MEASLES ANTIBODY; MEASLES VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SYNDROME;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DEMYELINATING DISEASES; FEMALE; HUMANS; MALE; MEASLES; MEASLES VACCINE; MIDDLE AGED; MULTIPLE SCLEROSIS; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 79957993702     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.04.002     Document Type: Article

References (37)

1. Adams J.M., Imagawa D.T. Measles antibodies in multiple sclerosis. Proc. Soc. Exp. Biol. Med. 1962, 111:562-566.
2. Adams J.M., Brooks M.B., Fisher E.D., Tyler C.S. Measles antibodies in patients with multiple sclerosis and with other neurological and nonneurological diseases. Neurology 1970, 20(10):1039-1042.
3. Ahlgren C., Oden A., Toren K., Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol. Scand. 2009, 119(5):313-320.
4. Ahlgren C., Toren K., Oden A., Andersen O. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur. J. Epidemiol. 2009, 24(9):541-552.
5. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57(8):897-902.
6. Bager P., Nielsen N.M., Bihrmann K., Frisch M., Hjalgrim H., Wohlfart J., Koch-Henriksen N., Melbye M., Westergaard T. Childhood infections and risk of multiple sclerosis. Brain 2004, 127(Pt 11):2491-2497.
7. Bednarova J., Stourac P., Adam P. Relevance of immunological variables in neuroborreliosis and multiple sclerosis. Acta Neurol. Scand. 2005, 112(2):97-102.
8. Bottiger M., Christenson B., Romanus V., Taranger J., Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987, 295(6608):1264-1267.
9. Brettschneider J., Tumani H., Kiechle U., Muche R., Richards G., Lehmensiek V., Ludolph A.C., Otto M. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 2009, 4(11):e7638.
10. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 2002, 346(3):158-164.
11. Broliden K., Leven B., Arneborn M., Bottiger M. Immunity to measles before and after MMR booster or primary vaccination at 12years of age in the first generation offered the 2-dose immunization programme. Scand. J. Infect. Dis. 1998, 30(1):23-27.
12. Cherian T., Joseph A., John T.J. Low antibody response in infants with measles and children with subclinical measles virus infection. J. Trop. Med. Hyg. 1984, 87(1):27-31.
13. Christenson B., Bottiger M. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7years after the introduction of a two-dose schedule. Vaccine 1991, 9(5):326-329.
14. Davidkin I., Jokinen S., Broman M., Leinikki P., Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis. 2008, 197(7):950-956.
15. Fescharek R., Quast U., Maass G., Merkle W., Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14years of use I. Efficacy and analysis of vaccine failures. Vaccine 1990, 8(4):333-336.
16. Geeraedts F., Wilczak N., van Binnendijk R., De Keyser J. Search for morbillivirus proteins in multiple sclerosis brain tissue. Neuroreport 2004, 15(1):27-32.
17. Haghighi S., Andersen O., Rosengren L., Bergstrom T., Wahlstrom J., Nilsson S. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls. J. Neurol. 2000, 247(8):616-622.
18. Hussey G.D., Goddard E.A., Hughes J., Ryon J.J., Kerran M., Carelse E., Strebel P.M., Markowitz L.E., Moodie J., Barron P., Latief Z., Sayed R., Beatty D., Griffin D.E. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 1996, 173(6):1320-1326.
19. Isa M.B., Martinez L., Giordano M., Passeggi C., de Wolff M.C., Nates S. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin. Diagn. Lab. Immunol. 2002, 9(3):693-697.
20. Jarius S., Franciotta D., Bergamaschi R., Rauer S., Wandinger K.P., Petereit H.F., Maurer M., Tumani H., Vincent A., Eichhorn P., Wildemann B., Wick M., Voltz R. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 2008, 79(10):1134-1136.
21. Link H., Huang Y.M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 2006, 180(1-2):17-28.
22. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59(6):880-892.
23. Osterhaus A.D., de Vries P., van Binnendijk R.S. Measles vaccines: novel generations and new strategies. J. Infect. Dis. 1994, 170(Suppl 1):S42-S55.
24. Owens G.P., Bennett J.L., Gilden D.H., Burgoon M.P. The B cell response in multiple sclerosis. Neurol. Res. 2006, 28(3):236-244.
25. Owens G.P., Bennett J.L., Lassmann H., O'Connor K.C., Ritchie A.M., Shearer A., Lam C., Yu X., Birlea M., DuPree C., Williamson R.A., Hafler D.A., Burgoon M.P., Gilden D. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009, 65(6):639-649.
26. Panelius M., Salmi A., Halonen P.E., Kivalo E., Rinne U.K., Penttinen K. Virus antibodies in serum specimens from patients with multiple sclerosis, from siblings, and matched controls. A final report. Acta Neurol. Scand. 1973, 49(1):85-107.
27. Panum P.L. Observations Made During the Epidemic of Measles on the Faroe Islands in the Year 1846 Med Classics 3(May) 1939, 829-886.
28. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13(3):227-231.
29. Reiber H., Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin. Chem. 1991, 37(7):1153-1160.
30. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 1998, 4(3):111-117.
31. Reiber H., Teut M., Pohl D., Rostasy K.M., Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult. Scler. 2009, 15(12):1466-1480.
32. Salmi A., Panelius M., Vainionpaa R. Antibodies against different viral antigens in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Acta Neurol. Scand. 1974, 50(2):183-193.
33. Sonoda S., Nakayama T. Detection of measles virus genome in lymphocytes from asymptomatic healthy children. J. Med. Virol. 2001, 65(2):381-387.
34. Strebel P.M., Papania M.J., Halsey N.A. Measles vaccine. Vaccines 2004, 389-440. Saunders, Philadephia. S.A. Plotkin, W.A. Orenstein (Eds.).
35. Strom J. [A new health card.] in Swedish. Sven. Lakartidn. 1959, 56:3526-3528.
36. Sundstrom P., Juto P., Wadell G., Hallmans G., Svenningsson A., Nystrom L., Dillner J., Forsgren L. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62(12):2277-2282.
37. Taranger J. In Swedish. Lakartidningen 1982, 79(39):3430-3431.